medium impactScope of Practicepharmacist OUD treatment authority; inter-professional competitive landscapeMaryland

Maryland expands pharmacist scope to include opioid use disorder treatment

June 25, 2026Source: Becker's Behavioral HealthBill: HB 838Status: signedEffective: July 1, 2025
52
Relevance score
Related policy

Impact on your practice

This expansion of pharmacist authority in OUD treatment affects therapists' competitive positioning and collaborative care model design. Therapists should understand that pharmacists now have direct prescribing authority for buprenorphine in Maryland, potentially reducing reliance on physicians and creating new inter-professional boundaries. For practices treating OUD, this changes referral patterns and may increase need for clear role definition in collaborative teams.

Key facts

1

Maryland HB 838 eliminates requirement for prescriber-pharmacist agreements to be filed with health occupations board, streamlining collaborative practice

2

Authorizes qualified pharmacists to prescribe buprenorphine for opioid use disorder treatment under prescriber-pharmacist agreements

3

Pharmacists must meet registration, training, protocol requirements and review PDMP data before initiating/modifying controlled substance therapy

4

Aligns with federal SUPPORT Act (Dec 2025) which explicitly authorized pharmacist buprenorphine prescribing at federal level

5

Part of broader national trend: 17 states recently proposed expanding pharmacist scope, signaling workforce competition in addiction/chronic disease management

States affected

Maryland
Analysis by Therapy Companion AI policy engineConfidence: highAnalyzed: June 26, 2026

Policy changes drive denial patterns

Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.

Related policy changes